NEELS GUIDO J 4

What Happened

• Guido J. Neels, a director of TELA Bio, received a package of equity awards on June 9, 2026 totaling 58,485 shares: 11,925 RSUs, 11,675 RSUs, 17,550 option-based awards, and 17,335 option-based awards. Each line was recorded at an acquisition price of $0.00 (standard for grants/awards).
• These were grants (award/acquisition), not open-market purchases or sales — they increase potential future ownership if vesting conditions are met.

Key Details

• Transaction date: June 9, 2026; Form 4 filed June 11, 2026 (appears timely).
• Awards granted: 11,925 RSUs (F1), 11,675 RSUs (F2), 17,550 option-type awards (F3), 17,335 option-type awards (F4). Total = 58,485 shares.
• Price: $0.00 recorded for each grant (reflects grant, not cash purchase).
• Shares owned after transaction: not specified in the filing summary provided.
• Notable vesting terms:
  • F1 (11,925 RSUs): vest in three equal annual installments beginning June 9, 2027, subject to continued service.
  • F2 (11,675 RSUs): vest on the earlier of June 9, 2027, the next annual meeting, or a Change in Control, subject to continued service.
  • F3 (17,550 option awards): vest in 36 equal monthly installments beginning June 9, 2026, subject to continued service.
  • F4 (17,335 option awards): vest on the earlier of June 9, 2027, the next annual meeting, or a Change in Control, subject to continued service.

Context

• These entries are awards/grants to a director and do not represent buying or selling in the open market. Grants are commonly used for compensation and retention; they become economically relevant only as they vest and, for options, if exercised.
• For retail investors, new grants increase potential future dilution but do not by themselves signal immediate insider buying or selling.